Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia

NCT00789906 | Unknown

• 1 other identifier: 223CTIL
• Study Type: observational
• Target: 700
• Locations: 1 country
• Sites: 1

Brief Summary

Schizophrenia affects cognition, emotion, and behavior. Neuropsychological assessment enables a better understanding of antipsychotic effectiveness and the brain processes, underlying cognitive functioning in schizophrenia. Neurocognitive deficits in schizophrenia patients appears to explain up to 61% of the variance of functional outcome and is an important predictor of social reintegration (Peuskens et al, 2005) and independent living activitiy (Green et al, 2004). Impaired social functioning within schizophrenia population has been associated with increased health-care costs. Since social and occupational disability may generate the largest indirect costs of the illness, treatment of cognitive deficits has an enormous impact on the cost and disability associated with schizophrenia (McGurk and Mueser, 2004). However, the gap between cognitive science and clinical practice limits the implementation of cognitive assessment in the routine evaluation of schizophrenia patients. Pharmaceutical industry initiated numerous large scale, multisite studies on the impact of novel antipsychotics on cognitive deficits in schizophrenia patients. The aim of this research is to develop population norms of the computerized neuropsychological assessment for effectiveness of the antipsychotic treatment in schizophrenia.

Conditions

Schizophrenia

Keywords

Computerized Neuropsychological Assessment; Development of Population Norms of the Computerized Neuropsychological Assessment

Study Arms (2)

1

350 healthy women , aged from 18 to 89

2

350 healthy men, aged from 18 to 89

Eligibility Criteria

• Age: 18 Years - 89 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

700 healthy adults (350 women and 350 men, aged from 18 to 89)

You may qualify if:

• An IQ, which is within normal range.

You may not qualify if:

• Psychiatric co-morbidity.
• Physical disability or illness.
• A history of severe head injury.

Sponsors & Collaborators

• BeerYaakov Mental Health Center: lead

Study Sites (1)

Beer-Yaacov MHC

Beer Yaacov, 70350, Israel

RECRUITING

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Central Study Contacts

Semyon Kertzman, MD

CONTACT

972-8-9776136; research@beerness.health.gov.il

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV

Study Record Dates

• First Submitted: November 11, 2008
• First Posted: November 13, 2008
• Study Start: July 1, 2008
• Last Updated: November 13, 2008

Record last verified: 2008-11

Locations

IL (1)